journal
Journals Cancer Chemotherapy and Pharma...

Cancer Chemotherapy and Pharmacology

https://read.qxmd.com/read/38536443/a-polo-like-kinase-1-inhibitor-enhances-erastin-sensitivity-in-head-and-neck-squamous-cell-carcinoma-cells-in-vitro
#1
JOURNAL ARTICLE
Xiangping Wu, Jing Wu
BACKGROUND: Polo-like kinase 1 (PLK1) is a critical therapeutic target in the treatment of head and neck squamous cell carcinoma (HNSCC). The objective of this study was to investigate the therapeutic effect of the combination of BI 2536, a PLK1 inhibitor, and erastin, a ferroptosis inducer, in HNSCC. METHODS: The proliferation, invasion, and migration abilities of Tu177 and FaDu cells upon exposure to BI 2536 and erastin, used in combination or alone, were tested...
March 27, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38530444/correction-to-inhibition-of-proteinase-activated-receptor-2-par2-decreased-the-malignant-progression-of-lung-cancer-cells-and-increased-the-sensitivity-to-chemotherapy
#2
Hongjie Huo, Yu Feng, Qiong Tang
No abstract text is available yet for this article.
March 26, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38520557/postoperative-chemotherapy-relative-dose-intensity-and-overall-survival-in-patients-with-colon-cancer
#3
JOURNAL ARTICLE
Justin C Brown, Jeffrey A Meyerhardt, Shengping Yang, Bette J Caan
PURPOSE: Quantifying the association of chemotherapy relative dose intensity (RDI) with overall survival may enable supportive care interventions that improve chemotherapy RDI to estimate their magnitude of potential clinical benefit. METHODS: This cohort study included 533 patients with stage II-III colon cancer who initiated a planned regimen of 12 cycles of 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy. The primary exposure was chemotherapy RDI...
March 23, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38520556/pharmacology-and-pharmacokinetics-of-tazemetostat
#4
JOURNAL ARTICLE
Marco Orleni, Jan H Beumer
Tazemetostat, a novel oral selective inhibitor of enhancer of zeste homolog 2 (EZH2), was approved by the Food and Drug Administration (FDA) in 2020 for use in patients with advanced epithelioid sarcoma or relapsed/refractory (R/R) EZH2-mutated follicular lymphoma. These indications were approved by the FDA trough accelerated approval based on objective response rate and duration of response that resulted from phase 2 clinical trials. Tazemetostat competes with S-adenosylmethionine (SAM) cofactor to inhibit EZH2, reducing the levels of trimethylated lysine 27 of histone 3 (H3K27me3), considered as pharmacodynamic marker...
March 23, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38507062/pharmacokinetics-mass-balance-and-metabolism-of-14-c-envonalkib-tq-b3139-a-novel-alk-tyrosine-kinase-inhibitor-in-healthy-chinese-subjects
#5
JOURNAL ARTICLE
Sheng Ma, Xin Wang, Shu Yan, Liyan Miao, Xiaojing Wan, Dawei Ding, Ding Yu, Xingxing Diao, Xunqiang Wang, Hua Zhang
PURPOSE: Envonalkib (TQ-B3139) is a novel, potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor used to treat ALK-positive non-small cell lung cancer. This phase I mass balance study investigated the pharmacokinetics, metabolism, and excretion of 14 C-radiolabeled envonalkib in healthy Chinese male subjects. METHODS: A single oral dose of 600 mg (150 µCi) [14 C]envonalkib was administered to healthy male subjects under fasted state. Samples of blood, urine and feces were collected for quantitative determination of total radioactivity and unchanged envonalkib, and the metabolites identification...
March 20, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38502348/berberine-chloride-suppresses-pancreatic-adenocarcinoma-proliferation-and-growth-by-targeting-inflammation-related-genes-an-in-silico-analysis-with-in-vitro-and-vivo-validation
#6
JOURNAL ARTICLE
Lin-Jie Ruan, Ju-Ying Jiao, Chienshan Cheng, Yuan Zhang, Zhang-Qi Cao, Ba He, Zhen Chen
PURPOSE: Targeting inflammatory crosstalk between tumors and their microenvironment has emerged as a crucial method for suppressing pancreatic adenocarcinoma (PAAD) progression. Berberine (BBR) is a natural pentacyclic isoquinoline alkaloid known for its anti-inflammatory and antitumor pharmacological effects; however, the mechanism underlying PAAD suppression remains unclear. We aim to investigate the effects of BBR on PAAD progression and their underlying mechanisms. METHODS: The prognostic value of inflammation-related genes in PAAD was assessed using bioinformatics analyses, then the pharmacological effects and potential mechanisms of BBR on PAAD will be investigated in silico, in vitro, and in vivo...
March 19, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38483557/the-effect-of-liver-dysfunction-on-the-pharmacokinetic-disposition-of-belinostat-and-its-five-metabolites-in-patients-with-advanced-cancers
#7
JOURNAL ARTICLE
Allison Dunn, Naoko Takebe, Alice Chen, Shivaani Kummar, Richard Piekarz, Brian Kiesel, Nancy Moore, James Doroshow, Jan H Beumer, Jogarao V S Gobburu
Belinostat was approved in 2014 for the treatment of relapsed or refractory peripheral T-cell lymphoma, however, there was insufficient data to recommend a dose in patients with moderate to severe hepatic impairment. The purpose of this analysis was to characterize the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers and varying degrees of liver dysfunction. A population pharmacokinetic model was therefore developed to describe the parent-metabolite system...
March 14, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38478074/phase-2-study-of-glucarpidase-in-patients-with-delayed-methotrexate-elimination-after-high-dose-methotrexate-therapy
#8
JOURNAL ARTICLE
Atsushi Ogawa, Hiroshi Kawamoto, Junichi Hara, Atsushi Kikuta, Chitose Ogawa, Hiroaki Hiraga, Kenichi Yoshimura, Kazunari Miyairi, Reiko Omori, Tokihiro Ro, Yuna Kamei, Toshimi Kimura
PURPOSE: High-dose methotrexate therapy (HD-MTX) is a standard treatment for various malignant tumors, but approximately 1-10% of patients experience delayed MTX elimination (DME) that can induce organ damage. Glucarpidase can hydrolyze MTX and thereby lower the level of active MTX in the blood. A multicenter, open-label, phase II investigator-initiated trial (CPG2-PII study) was conducted to evaluate glucarpidase rescue therapy in Japanese patients who showed DME after HD-MTX treatment...
March 13, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38459188/association-of-vegfa-and-ccl4l2-polymorphisms-with-hand-foot-skin-reaction-and-survival-of-regorafenib-in-japanese-patients-with-colorectal-cancer
#9
JOURNAL ARTICLE
Koutaro Ono, Remi Murase, Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Ken-Ichi Fujita
PURPOSE: Treatment with regorafenib, which inhibits vascular endothelial growth factor (VEGF) receptor, frequently results in hand-foot skin reaction (HFSR), requiring treatment discontinuation or dose reduction. In our prospective study of regorafenib on patients with metastatic colorectal cancer, 17% of patients developed grade 3 HFSR. Herein, we retrospectively examined genetic polymorphisms associated with regorafenib-induced severe HFSR. METHODS: To identify associated polymorphisms, exploratory whole-exome sequencing focusing on factors related to VEGF-mediated signaling pathways was first performed in seven patients each, with grade 3 HFSR and without HFSR...
March 8, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38456956/vitamin-d-suppresses-cd133-cd44%C3%A2-%C3%A2-cancer-stem-cell-stemness-by-inhibiting-nf-%C3%AE%C2%BAb-signaling-and-reducing-nlrp3-expression-in-triple-negative-breast-cancer
#10
JOURNAL ARTICLE
Wei Zheng, Wei Peng, Fuyong Qian, Mingshuai Zhang, Bofeng Duan, Zhifeng Fan, Yi Xie, Xiaoying Fu
BACKGROUND AND OBJECTIVE: This study aims to investigate the role of Vitamin D (VD) in regulating the stemness and survival of CD133+/CD44 + breast cancer stem cells, and to explore the role of NLRP3 in this process. METHODS: Breast cancer tissues were collected for RXRα and VDR expression analysis. A triple-negative breast cancer cell line was cultured and stem-like cells (CD133 + CD44+) isolated using flow cytometry. These cells were treated with VD, analyzing their stem-like properties, apoptosis and proliferation, as well as P65 nuclear expression and NLRP3 expression...
March 8, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38456955/impact-of-loperamide-on-the-pharmacokinetics-and-tissue-disposition-of-ritonavir-boosted-oral-docetaxel-therapy-a-preclinical-assessment
#11
JOURNAL ARTICLE
Nancy H C Loos, Viët Bui, Daniëlle H de Jong, Maria C Lebre, Hilde Rosing, Jos H Beijnen, Alfred H Schinkel
PURPOSE: An oral docetaxel formulation boosted by the Cytochrome P450 (CYP) 3 A inhibitor ritonavir, ModraDoc006/r, is currently under clinical investigation. Based on clinical data, the incidence of grade 1-2 diarrhea is increased with this oral docetaxel formulation compared to the conventional intravenous administration. Loperamide, a frequently used diarrhea inhibitor, could be added to the regimen as symptomatic treatment. However, loperamide is also a substrate of the CYP3A enzyme, which could result in competition between ritonavir and loperamide for this protein...
March 8, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38456954/low-serum-concentrations-of-bevacizumab-and-nivolumab-owing-to-excessive-urinary-loss-in-patients-with-proteinuria-a-case-series
#12
JOURNAL ARTICLE
Takashi Masuda, Taro Funakoshi, Takahiro Horimatsu, Shinya Yamamoto, Takeshi Matsubara, Sho Masui, Shunsaku Nakagawa, Yasuaki Ikemi, Motoko Yanagita, Manabu Muto, Tomohiro Terada, Atsushi Yonezawa
PURPOSE: Proteinuria can cause interindividual variability in the pharmacokinetics of therapeutic antibodies and may affect therapeutic efficacy. Here, we measured the serum and urinary concentrations of bevacizumab (BV) and nivolumab (NIVO) in patients with proteinuria and reported a case series of these patients. METHODS: Thirty-two cancer patients who received BV every 3 weeks or NIVO every 2 weeks between November 2020 and September 2021 at Kyoto University Hospital were enrolled in this study...
March 8, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38453720/pharmacokinetic-and-bioequivalence-study-of-two-capecitabine-tablets-in-chinese-patients-with-solid-tumor-cancer
#13
JOURNAL ARTICLE
Guangnan Zong, Jinlin Li, Xiushan Gong, Yuanyuan Liu, Xiuli Guo
Capecitabine (CAP) is one of the fluoropyrimidine deoxynucleoside carbamates, which can be converted to 5-fluorouracil (5-FU) by thymine deoxynucleoside phosphorylase (dThdPase) to exert antitumor effects. The purpose of this study is to compare the pharmacokinetics (PK), bioequivalence (BE), and safety of two CAP tablets in Chinese patients with solid tumor cancer. The results showed that the geometric mean ratios (GMRs) of Cmax , AUC0-t and AUC0-∞ of CAP T/R reagent were 90.26%, 95.27%, and 95.07, respectively...
March 7, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38451273/phase-i-pharmacokinetic-safety-and-preliminary-efficacy-study-of-tiragolumab-in-combination-with-atezolizumab-in-chinese-patients-with-advanced-solid-tumors
#14
JOURNAL ARTICLE
Colby S Shemesh, Yongsheng Wang, Andrew An, Hao Ding, Phyllis Chan, Qi Liu, Yih-Wen Chen, Benjamin Wu, Qiong Wu, Xian Wang
PURPOSE: Tiragolumab is an immunoglobulin G1 monoclonal antibody targeting the immune checkpoint T cell immunoreceptor with immunoglobulin and immunoreceptor ITIM domains. Targeting multiple immune pathways may improve anti-tumor responses. The phase I YP42514 study assessed the pharmacokinetics (PK), safety, and preliminary efficacy of tiragolumab plus atezolizumab in Chinese patients with advanced solid tumors. METHODS: Adult patients from mainland China with Eastern Cooperative Oncology Group performance score 0/1, life expectancy of ≥ 12 weeks, and adequate hematologic/end organ function were eligible...
March 7, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38441626/predictive-performance-of-population-pharmacokinetic-models-of-imatinib-in-chronic-myeloid-leukemia-patients
#15
JOURNAL ARTICLE
Jaya Shree Dilli Batcha, Vikram Gota, Saikumar Matcha, Arun Prasath Raju, Mahadev Rao, Karthik S Udupa, Surulivelrajan Mallayasamy
BACKGROUND AND AIM: Chronic myeloid leukemia is a myeloproliferative neoplasm associated with the specific chromosomal translocation known as the Philadelphia chromosome. Imatinib is a potent BCR-ABL tyrosine kinase inhibitor, which is approved as the first line therapy for CML patients. There are various population pharmacokinetic studies available in the literature for this population. However, their use in other populations outside of their cohort for the model development has not been evaluated...
March 5, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38438807/correction-to-midostaurin-drug-interaction-profile-a-comprehensive-assessment-of-cyp3a-cyp2b6-and-cyp2c8-drug-substrates-and-oral-contraceptives-in-healthy-participants
#16
Romain Sechaud, Helen Gu, Gholamreza Rahmanzadeh, Amanda Taylor, Ovidiu Chiparus, Gopal Krishna Sharma, Astrid Breitschaft, Hans D Menssen
No abstract text is available yet for this article.
March 5, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38436714/visceral-obesity-and-sarcopenia-as-predictors-of-efficacy-and-hematological-toxicity-in-patients-with-metastatic-breast-cancer-treated-with-cdk-4-6-inhibitors
#17
JOURNAL ARTICLE
Kadriye Bir Yücel, Uguray Aydos, Osman Sütcüoglu, Atiye Cenay Karabörk Kılıç, Nuriye Özdemir, Ahmet Özet, Ozan Yazıcı
PURPOSE: We aimed to investigate whether visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and skeletal muscle area (SMA) index are predictive for efficacy and hematological toxicity in ER + HER2-metastatic breast cancer (BC) patients who received CDK 4/6 inhibitors. METHODS: This retrospective cohort study analyzed 52 patients who were treated with CDK 4/6 inhibitors between January 2018 and February 2021. The values of VAT, SAT, SMA indices and hematological parameters were noted before the start, at the third and sixth months of this treatment...
March 4, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38430307/utility-and-impact-of-quantitative-pharmacology-on-dose-selection-and-clinical-development-of-immuno-oncology-therapy
#18
REVIEW
Yan Ji, Sherwin K B Sy
Immuno-oncology (IO) therapies have changed the cancer treatment landscape. Immune checkpoint inhibitors (ICIs) have improved overall survival in 20-40% of patients with malignancies that were previously refractory. Due to the uniqueness in biology, modalities and patient responses, drug development strategies for IO differed from that traditionally used for cytotoxic and target therapies in oncology, and quantitative pharmacology utilizing modeling approach can be applied in all phases of the development process...
March 2, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38430306/successful-use-of-palbociclib-combined-with-venetoclax-and-azacitidine-in-an-adult-with-refractory-relapsed-therapy-related-acute-myeloid-leukemia
#19
JOURNAL ARTICLE
Wenqiang Qu, Jialing Lu, Yujie Ji, Zhewei He, Mengjia Hou, Dongyang Li, Yan Yang, Dan Liu, Suning Chen
BACKGROUND: Therapy-related acute myeloid leukemia (t-AML) is considered high risk as it related to prior exposure to cytotoxic chemotherapy agents for solid tumors or hematologic malignancies. Compared with de novo AML, t-AML is associated with lower remission rates, inferior overall survival (OS) and higher relapse rates. Many efforts have been devoted to improving the overall but with limited success, and novel strategy is thus highly needed. CASE DESCRIPTION: We reported one patient with refractory/relapsed t-AML was successfully treated with Palbociclib combined with Venetoclax and Azacytidine (AZA)...
March 2, 2024: Cancer Chemotherapy and Pharmacology
https://read.qxmd.com/read/38427065/impact-of-bariatric-surgery-on-oral-anticancer-drugs-an-analysis-of-real-world-data
#20
JOURNAL ARTICLE
Cedric Lau, Ma Ida Mohmaed Ali, Lishi Lin, Dorieke E M van Balen, Bart A W Jacobs, Bastiaan Nuijen, Robert M Smeenk, Neeltje Steeghs, Alwin D R Huitema
PURPOSE: The number of patients with bariatric surgery who receive oral anticancer drugs is rising. Bariatric surgery may affect the absorption of oral anticancer drugs. Strikingly, no specific drug dosing recommendations are available. We aim to provide practical recommendations on the application of oral anticancer drugs in patients who underwent bariatric surgery. METHODS: Patients with any kind of bariatric surgery were extracted retrospectively in a comprehensive cancer center...
March 1, 2024: Cancer Chemotherapy and Pharmacology
journal
journal
27426
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.